Toronto, Ontario–(Newsfile Corp. – September 21, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce it has initiated first steps towards a clinical sleep study for a structure/function claim for the Company’s…


Previous articleMindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018
Next articleAre Prodrugs the Next Wave of Psychedelic Drug Development?